BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22990939)

  • 1. A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer.
    Kumar R; Jain K; Beeke C; Price TJ; Townsend AR; Padbury R; Roder D; Young GP; Richards A; Karapetis CS
    Cancer; 2013 Feb; 119(4):722-8. PubMed ID: 22990939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer.
    Khattak MA; Townsend AR; Beeke C; Karapetis CS; Luke C; Padbury R; Maddern G; Roder D; Price TJ
    Eur J Cancer; 2012 Jun; 48(9):1293-8. PubMed ID: 22119202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
    Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.
    Tomita Y; Karapetis CS; Ullah S; Townsend AR; Roder D; Beeke C; Roy AC; Padbury R; Price TJ
    Acta Oncol; 2016; 55(4):480-5. PubMed ID: 26878155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor.
    Kumar R; Price TJ; Beeke C; Jain K; Patel G; Padbury R; Young GP; Roder D; Townsend A; Bishnoi S; Karapetis CS
    Clin Colorectal Cancer; 2014 Jun; 13(2):87-93. PubMed ID: 24373733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients.
    Sorbye H; Pfeiffer P; Cavalli-Björkman N; Qvortrup C; Holsen MH; Wentzel-Larsen T; Glimelius B
    Cancer; 2009 Oct; 115(20):4679-87. PubMed ID: 19562777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Watchful waiting" for metastatic colorectal cancer, antediluvian or an option to be considered again?
    Price TJ; Townsend AR; Beeke C; Bishnoi S; Padbury R; Maddern G; Karapetis CS
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):10-3. PubMed ID: 22369439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morbidity of adjuvant hepatic arterial infusion pump chemotherapy in the management of colorectal cancer metastatic to the liver.
    Martin RC; Edwards MJ; McMasters KM
    Am J Surg; 2004 Dec; 188(6):714-21. PubMed ID: 15619489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
    J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival of patients with advanced colorectal cancer may not be due to the response to chemotherapy.
    Stathopoulos GP; Rigatos SK; Malamos NA; Stathopoulos JG; Thallasinou P; Papazachariou E; Antoniou F; Kondopodis E; Xynotroulas J
    Oncol Rep; 2004 Dec; 12(6):1295-300. PubMed ID: 15547753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases?
    Reddy SK; Tsung A; Marsh JW; Geller DA
    J Surg Oncol; 2012 Jan; 105(1):55-9. PubMed ID: 21842519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
    Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
    J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy.
    Townsend AR; Bishnoi S; Broadbridge V; Beeke C; Karapetis CS; Jain K; Luke C; Padbury R; Price TJ
    Am J Clin Oncol; 2013 Feb; 36(1):49-52. PubMed ID: 22270106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.
    Klaver YL; Simkens LH; Lemmens VE; Koopman M; Teerenstra S; Bleichrodt RP; de Hingh IH; Punt CJ
    Eur J Surg Oncol; 2012 Jul; 38(7):617-23. PubMed ID: 22572106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and outcomes of metastatic colorectal cancer in Australia: defining differences between public and private practice.
    Field K; Shapiro J; Wong HL; Tacey M; Nott L; Tran B; Turner N; Ananda S; Richardson G; Jennens R; Wong R; Power J; Burge M; Gibbs P
    Intern Med J; 2015 Mar; 45(3):267-74. PubMed ID: 25403925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A
    J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
    Renouf DJ; Lim HJ; Speers C; Villa D; Gill S; Blanke CD; O'Reilly SE; Kennecke H
    Clin Colorectal Cancer; 2011 Jun; 10(2):97-101. PubMed ID: 21859560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.